Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Autor: Axel Grothey, Sara Lonardi, Victor Sandor, Neeltje Steeghs, Rona Yaeger, Elena Elez, Yong Sang Hong, Harpreet Wasan, Christina Guo, Jan H.M. Schellens, Tae Won Kim, Eric Van Cutsem, Ashwin Gollerkeri, Tormod Kyrre Guren, Fotios Loupakis, Line Schmidt Tarpgaard, Kati Maharry, Jayesh Desai, Lisa Anderson, Sergey Orlov, Aitana Calvo Ferrándiz, Jeroen Dekervel, Michael Braun, Per Pfeiffer, Asha Krishnan, Pilar García-Alfonso, Michael D Pickard, Scott Kopetz, Janna Christy-Bittel, Hendrik Tobias Arkenau, Takayuki Yoshino, Fortunato Ciardiello, Christopher Hunt Keir, Van Morris, Josep Tabernero

Publikováno v: Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, Wasan, H, Ciardiello, F, Loupakis, F, Hong, Y S, Steeghs, N, Guren, T K, Arkenau, H T, Garcia-Alfonso, P, Pfeiffer, P, Orlov, S, Lonardi, S, Elez, E, Kim, T W, Schellens, J H M, Guo, C, Krishnan, A, Dekervel, J, Morris, V, Ferrandiz, A C, Tarpgaard, L S, Braun, M, Gollerkeri, A, Keir, C, Maharry, K, Pickard, M, Christy-Bittel, J, Anderson, L, Sandor, V & Tabernero, J 2019, ' Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer ', New England Journal of Medicine, vol. 381, no. 17, pp. 1632-1643 . https://doi.org/10.1056/NEJMoa1908075

BACKGROUND: Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of path

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80ce4d5efea909032075f515edc5b20a
https://doi.org/10.1056/nejmoa1908075

Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib

Autor: Søren Cold, Anders Bonde Jensen, Tea M Bøttcher

Publikováno v: Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2− breast cancer with new targeted agents in combination with endocrine therapy : a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2-breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603

Introduction: Recently, new targeted agents have been developed, which can prolong the effect of endocrine treatment (ET) by targeting resistance pathways in HR+/HER2− advanced breast cancer. This review examines available studies of everolimus, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa0942932052480a705d1f354fa46e9
https://pubmed.ncbi.nlm.nih.gov/30375908

Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)

Autor: Carrieri, Maria Patrizia, Protopopescu, Camelia, Younossi, Zobair, Vilotitch, Antoine, Fontaine, Hélène, Petrov-Sanchez, Ventzislava, Marcellin, Fabienne, Carrat, Fabrice, Hézode, Christophe, Bourlière, Marc, Poncin, Eric, Botta-Friedland, Danièle, Fontanges, Thierry, Arpurt, Jean-Pierre, Bacq, Yannicq, Calès, Paul, Delasalle, Patrick, Ouzan, Denis, Nousbaum, Jean-Baptiste, Sylvain, Christine, Ribard, Didier, Gatineau-Sailliant, Gilles, de Montigny-Lenhardt, Stéphanie, Renard, Philippe, Pilette, Christophe, Denis, Jacques, Lascoux-Combe, Caroline, Abel, Laurent, Albert, Matthew, Chazouillères, Olivier, Dubuisson, Jean, Negro, Francesco, Pageaux, Georges-Philippe, Paradis, Valérie, Spire, Bruno, Taburet, Anne-Marie, Trinchet, Jean-Claude, Yazdanpanah, Yazdan, Dufour, Cécilie, Fréhaut, Céline, Pirot, Marion, Lesel, Aurélie, Zahraa, Nathalie, Chau, Frédéric

Publikováno v: The Patient-Patient-Centered Outcomes Research
The Patient-Patient-Centered Outcomes Research, 2017, 10 (5), pp.605-614. ⟨10.1007/s40271-017-0232-1⟩
The Patient-Patient-Centered Outcomes Research, Vol. 10, No 5 (2017) pp. 605-614

International audience; Objective We aimed to compare health-related quality of life (HRQL) during and after HCV treatment in patients receiving pegylated-interferon (PEG-IFN)-containing therapy (including boceprevir or telaprevir - ANRS CO20 CUPIC c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ff9a9084dace7c7dc34a62f21b4933e
https://hal.science/hal-01767765/document

Blood pressure response to six-minute walk test in hypertensive subjects exposed to high altitude: Effects antihypertensive combination treatment

Autor: Grzegorz Bilo, Sergio Caravita, Piergiuseppe Agostoni, José Luis Macarlupú, Cecilia Anza-Ramirez, Francisco C. Villafuerte, Morin Lang, Elisabetta Salvioni, Andrea Faini, Gianfranco Parati

Background: Limited evidence exists on blood pressure (BP) responses to exercise in hypertensive subjects exposed to high altitude, and on the effects of antihypertensive treatment in this setting. We aimed to asses BP response to submaximal exercise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd8b1c031aa5ca0b2d83dda91f7a053b
http://hdl.handle.net/10446/188872

Successful Antiparasitic Treatment for Cysticercosis Is Associated with a Fast and Marked Reduction of Circulating Antigen Levels in a Naturally Infected Pig Model

Autor: Pierre Dorny, Robert H. Gilman, Yesenia Castillo, Javier A. Bustos, Armando E. Gonzalez, Hector H. Garcia, Nicolas Praet, Silvia Rodriguez, Sarah Gabriël, Mirko Zimic

Taenia solium cysticercosis is a common parasitic infection of humans and pigs. We evaluated the posttreatment evolution of circulating parasite-specific antigen titers in 693 consecutive blood samples from 50 naturally infected cysticercotic pigs, w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d959acc9f459c6cb56ac25da4905d572
https://europepmc.org/articles/PMC4674250/